Mylan

Mylan is a leading global pharmaceutical company focused on the development, manufacturing, and distribution of generic and branded prescription medications. The company has built a reputation for providing affordable alternatives to branded drugs, with a portfolio that spans multiple therapeutic areas such as oncology, infectious diseases, cardiovascular health, and central nervous system disorders.

Operating in more than 165 countries, Mylan maintains an extensive network of manufacturing facilities across the world to ensure supply chain reliability. Its main activities include the production of complex generics, biosimilars, and specialty pharmaceuticals that address unmet medical needs.

The company was incorporated in the Netherlands as Mylan N.V. but is primarily based in Canonsburg, Pennsylvania, in the United States. In 2020, Mylan completed a merger with Upjohn, Pfizer's off-patent branded medicines business, resulting in the formation of Viatris Inc. This new entity continues many of Mylan's operations and product lines under the combined structure.

Within the pharmaceutical industry, Mylan has been recognized as one of the largest generic drug manufacturers, contributing significantly to healthcare accessibility by offering high-quality, lower-cost medications. Its position allows it to compete effectively in both developed and emerging markets.